SecBot SecBot
SECBOTREPLAY Home › Report › QTTB

QTTB · Q32 Bio announced positive 36-week topline results from Part B of the…

Q32 Bio Inc. · 8-K filed Jul 13, 2026 at 08:39 ET

At the news

BULLISHIMPACT 7/10

8-K filed Jul 13, 2026 at 08:39 ET

Q32 Bio announced positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a trial for bempikibart in severe/very severe alopecia areata. The mITT population (n=25) showed a 35.3% mean SALT reduction and 40.0% SALT-20 response, with no Grade 3 or higher adverse events and negligible anti-drug antibodies. The company plans to advance to a registration-directed program and engage the FDA in 1H27, supporting a differentiated biologic profile in a >$5B US market opportunity.

  • Part B mITT (n=25): 35.3% mean SALT reduction at Week 36; SALT-20 response 40.0% (10/25)
  • ITT (n=33): SALT-20 response 30.3% (10/33)
  • No Grade 3 or higher AEs; injection site reactions in 4% of administrations, all mild
  • Negligible anti-drug antibodies with no impact on pharmacokinetics

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access